| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| 2g | |||
| Other Sizes |
| Targets |
5,7-Dimethoxyflavone targets multiple pathways. It inhibits cytochrome P450 (CYP) 3A enzymes. In cancer cells, it induces the production of reactive oxygen species (ROS), leading to cell cycle arrest at the G1 phase and apoptosis. It has anti-obesity, anti-inflammatory, and antineoplastic effects. As a flavonoid, it may also interact with various signaling pathways involved in inflammation and metabolism.
|
|---|---|
| ln Vitro |
In MDCK/Bcrp1 cells, 5,7-Dimethoxyflavone (5 and 50 μM, 1 hour) inhibits Bcrp1-mediated sorafenib efflux [2]. In B16F10 melanoma cells, 5,7-dimethoxyflavone (0-25 μM, 48 hours) promotes melanogenesis by raising cAMP [4]. 5,7-dimethoxyflavone (0 - 100 μM, 48 hours) can block ischemia, promote oxidative termination, and trigger apoptosis in VK2/E6E7 and End1/E6E7 cells. It can also dilute the cells in cells by accumulation of TG in 3T3-L1 adipocytes [6].Cell.
In vitro, 5,7-Dimethoxyflavone induces the production of reactive oxygen species (ROS), cell cycle arrest at the G1 phase, and apoptosis in cancer cells. It inhibits cytochrome P450 (CYP) 3A enzymes. The compound has anti-obesity, anti-inflammatory, and antineoplastic effects. Its activity is typically evaluated using cell viability and proliferation assays in cancer cell lines, as well as enzyme inhibition assays for CYP3A. However, specific IC50 values are not extensively reported in the available literature. |
| ln Vivo |
In mouse liver, 5,7-dimethoxyflavone (10 mg/kg, facial, once daily for 10 days) can lower the expression levels of CYP3A11 and CYP3A25 proteins [1]. In HFD mice, 5,7-Dimethoxyflavone (25 and 50 mg/kg, face) and 5,7-Dimethoxyflavone (50 mg/kg/d, epidermis, for 6 weeks) decrease body weight while increasing and inhibiting liver function[5].
In vivo, 5,7-Dimethoxyflavone has been studied for its anti-obesity, anti-inflammatory, and antineoplastic effects. As a major component of Kaempferia parviflora, it contributes to the plant's traditional medicinal uses. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile. The compound is a research tool for studying flavonoid biology. |
| Enzyme Assay |
Cell-free assays for 5,7-Dimethoxyflavone involve evaluating its inhibitory activity against cytochrome P450 (CYP) 3A enzymes. Enzyme activity is monitored using fluorogenic or luminescent substrates. Inhibition is assessed by incubating CYP3A with varying concentrations of 5,7-Dimethoxyflavone and measuring residual activity. IC50 values are determined from dose-response curves. The compound's antioxidant activity can also be assessed using cell-free radical scavenging assays.
|
| Cell Assay |
Western Blot Analysis[4]
Cell Types: B16F10 melanoma cells Tested Concentrations: 0-25 μM Incubation Duration: 48 hrs (hours) Experimental Results: Induces CREB phosphorylation and inhibits Akt and GSK-3β phosphorylation. In vitro cellular assays for 5,7-Dimethoxyflavone typically involve treating cancer cells with various concentrations of the compound. Cells are incubated for defined periods (24-72 hours). Cell viability is assessed using MTT, CellTiter-Glo, or other standard assays. ROS production is measured using fluorescent probes such as DCFH-DA. Cell cycle analysis is performed using flow cytometry. Apoptosis is evaluated using Annexin V/PI staining and caspase activity assays. |
| Animal Protocol |
Animal/Disease Models: Aged mice [3]
Doses: 25 and 50 mg/kg Route of Administration: Oral Experimental Results: Increased grip strength and running endurance. Increase muscle size, weight, and cross-sectional area. Serum and gastrocnemius muscle IL-6 and TNF-α levels were diminished. In vivo animal studies for 5,7-Dimethoxyflavone are conducted in models of obesity, cancer, and inflammation. The compound is administered via various routes including oral gavage or dietary inclusion. Body weight and metabolic parameters are monitored in obesity models. Tumor growth is monitored in cancer models. Inflammatory markers are measured in serum and tissues. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5,7-Dimethoxyflavone include a molecular weight of 282.30 g/mol and molecular formula C17H14O4. As a flavonoid, it is expected to have moderate oral bioavailability. The compound is typically stored refrigerated (0-10°C). Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 5,7-Dimethoxyflavone has not been extensively characterized in published literature. As a natural flavonoid, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
5,7-Dimethoxyflavonoid 5,7-dimethyl ether is a dimethoxyflavonoid, a 5,7-dimethyl ether derivative of guarcin. It is a plant metabolite functionally related to guarcin. 5,7-Dimethoxyflavonoids have been reported in Boesenbergia rotunda, Kaempferia parviflora, and other organisms with relevant data.
5,7-Dimethoxyflavone is a flavonoid from Kaempferia parviflora with anti-obesity, anti-inflammatory, and antineoplastic effects. It inhibits CYP3A enzymes and induces ROS production, cell cycle arrest, and apoptosis in cancer cells. Its molecular formula is C17H14O4 with a molecular weight of 282.30 g/mol. 5,7-Dimethoxyflavone is a research tool for studying cancer, obesity, and inflammation. |
| Molecular Formula |
C17H14O4
|
|---|---|
| Molecular Weight |
282.2907
|
| Exact Mass |
282.089
|
| CAS # |
21392-57-4
|
| PubChem CID |
88881
|
| Appearance |
White to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
476.6±45.0 °C at 760 mmHg
|
| Melting Point |
150-152ºC
|
| Flash Point |
213.4±28.8 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.598
|
| LogP |
3.27
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JRFZSUMZAUHNSL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O4/c1-19-12-8-15(20-2)17-13(18)10-14(21-16(17)9-12)11-6-4-3-5-7-11/h3-10H,1-2H3
|
| Chemical Name |
5,7-dimethoxy-2-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~221.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5425 mL | 17.7123 mL | 35.4246 mL | |
| 5 mM | 0.7085 mL | 3.5425 mL | 7.0849 mL | |
| 10 mM | 0.3542 mL | 1.7712 mL | 3.5425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
